ACT016 (Inclusion Criteria)

Inclusion Criteria:

1. Patient is currently receiving treatment with ceritinib within a Novartis-sponsored study which has fulfilled the requirements for the primary objective and, in the opinion of the Investigator, would benefit from continued treatment.
2. Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
3. Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
4. Written informed consent obtained prior to enrolling in the roll-over study and receiving study medication. If consent cannot be expressed in writing, it must be formally documented and witnessed via an independent trusted witness.